Kestra Medical director sells 30,000 shares

The director's reported sale price was a weighted average of $30.0294 per share, with executions ranging from $30.0000 to $30.4202.

Rhea-AI Filing Summary

KESTRA MEDICAL TECHNOLOGIES, LTD. director and officer Traci S. Umberger exercised 30,000 options at $17 per share on October 27, 2026, acquiring 30,000 common shares, and sold 30,000 shares at a weighted average price of $30.0294 per share. The scheduled exercise and sale were pursuant to a Rule 10b5-1 plan adopted on July 21, 2026; sale prices ranged from $30.0000 to $30.4202. Her reported option position after the exercise was 411,000 options, including 365,919 fully vested options as of the filing date and 45,081 options vesting in equal monthly installments through March 6, 2027.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider Umberger Traci S

Role See Remarks

Sold 30,000 shs ($901K)

Approx. gross sale proceeds $901K

Approx. exercise cost $510K

Type	Security	Shares	Price	Value
Exercise	Options F3	30,000	$0.00	$0.00
Exercise	Common Shares F1	30,000	$17.00	$510K
Sale	Common Shares F1, F2	30,000	$30.0294	$901K

Holdings After Transaction: Options — 411,000 contracts (Direct); Common Shares — 195,825 shares (Direct)

Footnotes (3)

1. F1. This reported transaction is a scheduled exercise and sale pursuant to a Rule 10b5-1 trading plan adopted on July 21, 2026.
2. F2. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $30.0000 to $30.4202. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
3. F3. Includes 365,919 fully vested options as of the filing date, with the remaining 45,081 options vesting in equal monthly installments through March 6, 2027.

Key Figures

Options exercised: 30,000 options Exercise price: $17 per share Common shares acquired: 30,000 common shares +5 more

8 metrics

Options exercised 30,000 options October 27, 2026

Exercise price $17 per share Options exercised October 27, 2026

Common shares acquired 30,000 common shares October 27, 2026

Shares sold 30,000 shares October 27, 2026

Weighted average sale price $30.0294 per share Reported sale on October 27, 2026

Options following exercise 411,000 options Reported position following the exercise

Fully vested options 365,919 options As of the filing date

Options vesting 45,081 options Vesting in equal monthly installments through March 6, 2027

Key Terms

Rule 10b5-1 trading plan, weighted average price, fully vested options

3 terms

Rule 10b5-1 trading plan financial

"pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

fully vested options financial

"365,919 fully vested options"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many KMTS shares did Traci S. Umberger sell and at what price?

Traci S. Umberger sold 30,000 shares on October 27, 2026, at a weighted average price of $30.0294 per share; reported sale prices ranged from $30.0000 to $30.4202. The scheduled exercise and sale were pursuant to a Rule 10b5-1 trading plan adopted on July 21, 2026.

How many options did KMTS director Traci S. Umberger exercise?

She exercised 30,000 options at $17 per share on October 27, 2026, acquiring 30,000 common shares. Her reported option position following the exercise was 411,000 options; 365,919 were fully vested as of the filing date, with 45,081 vesting in equal monthly installments through March 6, 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/29/2026 - 06:44 PM EDT Accepted by SEC EDGAR 10/29/2026 - 06:44 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Umberger Traci S

(Last) (First) (Middle)

3933 LAKE WASHINGTON BLVD NE, SUITE 200

(Street)

KIRKLAND WASHINGTON 98033

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KESTRA MEDICAL TECHNOLOGIES, LTD. [ KMTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	10/27/2026		M(1)		30,000	A	$17	225,825	D
Common Shares	10/27/2026		S(1)		30,000	D	$30.0294(2)	195,825	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options	$17	10/27/2026		M			30,000	(3)	03/06/2035	Common Stock	30,000	$0	411,000	D

Explanation of Responses:

1. This reported transaction is a scheduled exercise and sale pursuant to a Rule 10b5-1 trading plan adopted on July 21, 2026.

2. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $30.0000 to $30.4202. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

3. Includes 365,919 fully vested options as of the filing date, with the remaining 45,081 options vesting in equal monthly installments through March 6, 2027.

Remarks:

General Counsel and Chief Adminstrative Officer

	/s/ Traci S. Umberger	10/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)